Efficacy of antimalarial treatment in Guinea: In vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zérékoré

Malaria Journal

Volumn 6, Issue , 2007, Pages

  Bonnet, Maryline ^a   Roper, Cally ^b   Félix, Martine ^c   Coulibaly, Léonie ^d   Kankolongo, Gabriel Mufuta ^c   Guthmann, Jean Paul ^a  

^a EPICENTRE   (France)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

^d National Malaria Control Program   (Guinea)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMISININ; ARTESUNATE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; FANSIDAR; MOLECULAR MARKER; QUININE; ARTEMISININ DERIVATIVE; PYRIMETHAMINE; SESQUITERPENE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CODON; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; GUINEA; HEALTH CARE POLICY; HUMAN; IN VIVO STUDY; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; ANIMAL; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; GENE; GENETIC MARKER; GENETICS; TREATMENT OUTCOME;

AMODIAQUINE; ANIMALS; ANTIMALARIALS; ARTEMISININS; CHILD, PRESCHOOL; DIHYDROPTEROATE SYNTHASE; DRUG COMBINATIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GENES, PROTOZOAN; GENETIC MARKERS; GENOTYPE; GUINEA; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; SESQUITERPENES; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE; TREATMENT OUTCOME;

EID: 34248398128     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-6-54     Document Type: Article

References (16)

1. Efficacy of amodiaquine for uncomplicated Plasmodium falciparum malaria in Harper, Liberia. F Checchi S Balkan BT Vonhm M Massaquoi P Biberson P Eldin de Pecoulas P Brasseur JP Guthmann, Trans R Soc Trop Med Hyg 2002 96 670 673 10.1016/S0035-9203(02)90348-2 12625148
2. High Plasmodium falciparum resistance to chloroquine and sulphadoxine-pyrimethamine in Harper, Liberia: results in vivo and analysis of point mutations. F Checchi R Durand S Balkan BT Vonhm JZ Kollie P Biberson E Baron J Le Bras JP Guthmann, Trans R Soc Trop Med Hyg 2002 96 664 669 10.1016/S0035-9203(02)90346-9 12625147
3. Evidence basis for antimalarial policy change in Sierra Leone: five in vivo efficacy studies of chloroquine, sulphadoxine-pyrimethamine and amodiaquine. F Checchi P Roddy S Kamara A Williams G Morineau AR Wurie B Hora N de Lamotte T Baerwaldt A Heinzelmann A Danks L Pinoges A Oloo R Durand L Ranford-Cartwright M De Met, Trop Med Int Health 2005 10 146 153 10.1111/j.1365-3156.2004.01367.x 15679557
4. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. World Health Organization, WHO, Geneva, WHO/HTM/RBM/2003.50 2003
5. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg 2000 94 Suppl 1 S1 90 11103309
6. Basic malaria microscopy. World Health Organization, Parts I and II. WHO Geneva 1991
7. An analysis of anemia and child mortality. BJ Brabin Z Premji F Verhoeff, J Nutr 2001 Suppl 131 636 646
8. Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the north western border of Thailand. A Brockman REL Paul T Anderson I Hackford L Phaiphun F Nosten KP Day, Am J Trop Med Hyg 1999 60 14 21 9988316
9. Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania. R-J Pearce C Drakeley D Chandramohan F Mosha C Roper, Antimicrob Agents Chemother 2003 47 1347 1354 12654669 10.1128/AAC.47.4.1347-1354.2003
10. Antifolate antimalarial resistance in southeast Africa: a population-based analysis. C Roper R Pearce B Bredenkamp J Gumede C Drakeley F Mosha D Chandramohan B Sharp, Lancet 2003 361 1174 1181 10.1016/S0140-6736(03) 12951-0 12686039
11. Plasmodium falciparum: evaluation of a quantitative nucleic acid sequence-based amplification assay to predict the outcome of sulphadoxine-pyrimethamine treatment of uncomplicated malaria. SA Omar PF Mens GJ Schoone A Yusuf J Mwangi S Kaniaru GA Omer HD Schallig, Exp Parasitol 2005 110 73 79 10.1016/j.exppara.2005.02.001 15804381
12. Molecular markers for failure of sulphadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. JG Kublin FK Dzinjalamala DD Kamwendo EM Malkin JF Cortese LM Martino RAG Mukadam SJ Rogerson AG Lescano ME Molyneux PA Winstanley P Chimpeni TE Taylor CV Plowe, J Infect Dis 2002 185 380 368 10.1086/338566 11807721
13. Sulphadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. G Dorsey D Njama MR Kamya A Cattamanchi D Kyabayinze SG Staedke A Gasasira PJ Rosenthal, Lancet 2002 360 2031 2038 10.1016/S0140-6736(02)12021-6 12504399
14. History and importance of antimalarial drug resistance. U D'Alessandro H Buttiëns, Trop Med Int Health 2001 6 845 848 10.1046/j.1365-3156.2001. 00819.x 11703837
15. Combination therapy for malaria in Africa: hype or hope? PB Bloland M Ettling S Meek, Bull World Health Organ 2002 78 1378 1388
16. Combination therapy for malaria: the way forward? F Nosten P Brasseur, Drugs 2002 62 1325 1329 10.2165/00003495-200262090-00003